Editas Medicine's GAAP loss for three months of 2021 was $56.728 million, up 50.4% from $37.724 million in the prior year. Revenue increased 13.6% to $6.499 million compared to $5.723 million a year earlier.
Editas Medicine's GAAP loss for three months of 2021 was $56.728 million, up 50.4% from $37.724 million in the prior year. Revenue increased 13.6% to $6.499 million compared to $5.723 million a year earlier. 
ir.editasmedicine.com
English (US) 